Module

Follicular NHL and Marginal Zone MALT-type Lymphomas

Source: Lymphoma Annual Update 2005

Follicular NHL and Marginal Zone MALT-type Lymphomas


Program Director: Julie M. Vose, MD

Faculty:

  • Myron S. Czuczman, MD

CME CREDIT INFORMATION

Release Date: 09/14/05

Expiration Date: 09/13/06


Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.9 Nursing CE credits

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the use of rituximab in the treatment of follicular non-Hodgkin's lymphoma.

  • Discuss novel treatments, including monoclonal antibodies, stem cell transplantation, radioimmunotherapy, and vaccine therapy, currently being evaluated in clinical trials for patients with follicular non-Hodgkin's lymphoma and MALT-type lymphomas.

  • Review current therapeutic strategies for the treatment of follicular non-Hodgkin's and MALT-type lymphomas.


Content includes:

  • Follicular NHL and Marginal Zone MALT-type Lymphomas
  • Improving Outcomes and Optimizing Treatment in FL Patients
  • Rituximab Combinations in Follicular NHL
  • Maintenance Rituximab: Prolonging Remission in Patients With Follicular Lymphoma
  • Other Antibody Therapies for Follicular NHL
  • Radiolabeled Antibody Therapy for Follicular NHL
  • Stem Cell Transplantation for Follicular NHL
  • Vaccine Therapy and Immunomodulatory Drugs for Follicular NHL
  • Proteasome Inhibition for Follicular NHL
  • Antisense Therapy for Follicular NHL
  • Treatment Advances in Marginal Zone MALT-type lymphomas
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grants provided by:

Educational grants support only the CME-certified components of this program.